1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Hematologic Cancer: new trials by email Literature Review of Hematologic Cancer trials Research Report on Hematologic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Azacitidine, all trans retinoic acid - AML, MDS | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 180 | 2021-05-01 | 2022-01-03 |
Frailty (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (1) · Tretinoin (1)
The First Affiliated Hospital of Soochow University (1)
China (1)
Han Yue, Ph.D (1)